Investegate |eureKARE Announcements | eureKARE: eureKARE invests in Coave Therapeutics as part of its €33 million Series B round investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Congenica Receives CE Mark for Genomic Analysis Software
Cambridge, United Kingdom -
202
1 - Congenica, the digital health company enabling rapid and accurate analysis of complex genomic data to transform people s lives, today announces that its genomic interpretation software is now CE marked under the In Vitro Diagnostics Directive (98/79/EC).
With the In Vitro Diagnostic (IVD) designation, Congenica s clinical decision support platform can make the transition from research to clinical use and be applied to the clinical diagnosis of patients with rare hereditary genomic disorders. The platform is the only CE marked IVD software for genomic diagnostics that is available either on a local infrastructure or via the cloud and can be fully integrated with existing medical records and laboratory management systems. Medical devices require the CE mark designation for use in clinical applications in several key territories including the UK and the EU.
eureKARE invests in Coave Therapeutics as part of its €33 million Series B round finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Oxford, U.K. 19 July 2021: Sensyne Health plc (LSE: SENS) ( Sensyne or the Company ), the ethical AI company, announces an update on its strategy which now includes exploring a potential dual-listing on Nasdaq amongst other options. As stated in our financial year end trading update on 27 May 2021, the Company continues to explore strategic opportunities, including making acquisitions, that leverage its organic growth and create additional shareholder value. Any decision to list in the US would complement the Company s primary listing on the AIM market of the London Stock Exchange and Sensyne remains committed to being a UK-headquartered company. Any acquisition or strategic equity partnership would
Sensyne Health PLC (AIM:SENS) | RNS | Sensyne Health PLC - Sensyne Health Provides Strategic Update proactiveinvestors.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.co.uk Daily Mail and Mail on Sunday newspapers.